About Dry Eye Syndrome
Dry eye syndrome is a prevalent and often chronic condition estimated to affect approximately 20 million people in the U.S. It is among the most common diseases treated by ophthalmologists throughout the world, and has been shown to have a significant impact upon quality of life. Dry eye varies in severity and etiology, and symptoms most commonly manifest as discomfort, visual disturbances, and tear film instability due to decreased quality or quantity of tears. A major contributing factor towards the development of dry eye is inflammation caused by T-cell infiltration, proliferation and inflammatory cytokine production that can lead to reduction in tear film quality and ocular surface damage.
About SAR 1118
SAR 1118 is a potent novel small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonist that can be targeted against a broad range of ocular inflammatory conditions including dry eye, uveitis, and diabetic macular edema. LFA-1 is member of the integrin family of adhesion receptors found on the surface of all leukocytes and represents a therapeutic target central to a number of inflammatory stimuli. SAR 1118 has demonstrated significant potency in inhibiting cell adhesion, cytokine production, and cellular proliferation in in vitro models. In a recent Phase 2 dry eye trial, it demonstrated clear improvements in both signs and symptoms of dry eye as early as 12 weeks.
About SARcode Corporation
SARcode Corporation, founded in 2006, is venture-backed ophthalmic biopharmaceutical company based in San Francisco, CA. SARcode's lead development program is a nov
|SOURCE SARcode Corporation|
Copyright©2010 PR Newswire.
All rights reserved